Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV.

Annals of hepatology - 1 Jan 2000

Rodriguez-Torres Maribel, Yoshida Eric M, Marcellin Patrick, Srinivasan Subasree, Purohit Vivek S, Wang Cunshan, Hammond Jennifer L

Abstract excerpt

OBJECTIVES: Filibuvir is a non-nucleoside inhibitor of hepatitis C virus (HCV) polymerase. This study evaluated the safety and efficacy of filibuvir plus pegylated interferon alfa-2a (pegIFN)/ribavirin. MATERIAL AND METHODS: Treatment-naïve, HCV genotype-1 patients were randomized to receive fili...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polyethylene Glycols

Share to Pyrones

Share to Ribavirin

Share to Triazoles

Share to Viral Load

Source

Identifiers

PMID: 24927607

Genes

BID

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24927607-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV.PMID 24927607Read ↗

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.Semantic proximity Read ↗

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1Semantic proximity Read ↗

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.Semantic proximity Read ↗

Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.Semantic proximity Read ↗

A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.Semantic proximity Read ↗

Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.Semantic proximity Read ↗

Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.Semantic proximity Read ↗

A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.